Ulisse Biomed Logo

Ulisse Biomed

Develops an integrated platform for distributed and connected diagnostic solutions.

UBM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005451213 (+1 more)
LEI:
815600F9C180B297BE35
Country:
Italy
Address:
VIA AQUILEIA, 17, 33100 UDINE

Description

Ulisse Biomed is a healthcare biotechnology company specializing in distributed and connected diagnostic solutions. The company develops an integrated platform that includes miniaturized qPCR instruments, an AI-driven cloud-based software, and advanced multiplexing reagents. This technology enables genetic testing for a wide range of users, from large clinical and diagnostic laboratories to smaller, peripheral labs in industrial settings. Its primary markets are healthcare and diagnostics, serving hospitals and clinics, and the agrifood and nutraceutical sectors. The company also provides OEM and development services. In late 2025, shareholders approved a proposal to change the corporate name to Helyx Industries S.p.A.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 08:16
EFFICACIA DEL CAMBIO DI DENOMINAZIONE SOCIALE DA ULISSE BIOMED S.P.A. A HELYX I…
Italian 396.5 KB
2025-12-05 23:44
MATURAZIONE DELLA SECONDA TRANCHE DEL PIANO DI STOCK GRANT 2024-2028
Italian 189.1 KB
2025-12-02 17:46
L’ASSEMBLEA DEGLI AZIONISTI HA APPROVATO LA PROPOSTA DI VARIAZIONE DELLA DENOM…
Italian 201.4 KB
2025-12-01 17:14
RINVIO ASSEMBLEA STRAORDINARIA IN SECONDA CONVOCAZIONE
Italian 205.4 KB
2025-11-24 23:39
ULISSE BIOMED S.P.A. RICEVE UN ORDINE SIGNIFICATIVO PER LA FORNITURA DI PRODOTT…
Italian 172.2 KB
2025-11-21 15:31
SOTTOSCRITTO PER EURO 537.200 L’AUMENTO DI CAPITALE SOCIALE DELIBERATO DAL CONS…
Italian 184.5 KB
2025-11-15 12:14
CONVOCAZIONE DELL’ASSEMBLEA STRAORDINARIA DEGLI AZIONISTI E DEPOSITO DELLA DOCU…
Italian 200.9 KB
2025-11-13 19:29
IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOC…
Italian 242.0 KB
2025-10-31 17:55
CHIUSURA OTTAVO PERIODO DI ESERCIZIO WARRANT
Italian 222.3 KB
2025-09-30 18:02
APERTURA DELL’OTTAVO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 202…
Italian 208.5 KB
2025-09-30 17:54
IL CONSIGLIO DI AMMINISTRAZIONE DI ULISSE BIOMED APPROVA LA RELAZIONE SEMESTRAL…
Italian 683.5 KB
2025-09-05 20:05
ULISSE BIOMED S.P.A. INDIVIDUA BANCA FINNAT COME INTERMEDIARIO PER LA NEGOZIAZI…
Italian 207.5 KB
2025-07-31 19:58
SIGNED AN INVESTMENT AGREEMENT WITH U.S. INVESTOR GLOBAL CORPORATE FINANCE
English 323.4 KB
2025-07-31 19:37
SOTTOSCRITTO UN ACCORDO DI INVESTIMENTO CON L’INVESTITORE STATUNITENSE GLOBAL C…
Italian 540.4 KB
2025-07-23 18:37
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Italian 255.4 KB

Automate Your Workflow. Get a real-time feed of all Ulisse Biomed filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ulisse Biomed

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ulisse Biomed via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

A clinical-stage biotech developing nanomedicines for oncology and diagnostics.
Malaysia
N/A
Metagenomi, Inc. Logo
A genetic medicines company developing therapeutics with a genome editing toolbox.
United States of America
MGX
MindWalk Holdings Corp. Logo
A Bio-Native AI company that integrates AI and lab research for drug discovery.
United States of America
HYFT
Mips Logo
Specializes in helmet-based safety technology to redirect rotational motion.
Sweden
MIPS
A think tank offering research, consulting, and ICT solutions for societal issues.
Japan
3636
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing a polysaccharide for systemic inflammation.
Sweden
MODTX
Molecure S.A. Logo
Clinical-stage biotech developing small molecule drugs for oncology and fibrotic diseases.
Poland
MOC
Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and rare diseases.
United States of America
MNPR
Mural Oncology PLC Logo
Clinical-stage biotech developing novel cytokine-based cancer immunotherapies.
Ireland
MURA
N4 PHARMA PLC Logo
Develops a silica nanoparticle delivery system for nucleic acid-based treatments.
United Kingdom
N4P

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.